Igniting a New Era in Health

Emulate Closes $82M Series E Financing 


Organ‑Chips Overview

Emulate develops and manufactures next-generation in vitro biological models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods.

Organ-on-a-Chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body. The technology is used by leading academic researchers, government entities, and many of the largest pharmaceutical companies to better understand the biology of human disease. 

Press Release

Emulate Closes $82 Million Series E Financing to Scale Amid Rapid Growth in Organ-on-a-Chip Market  

Company plans to expand research and development and scale commercial organization to support global customer base.

Med City News

Emulate CEO Spotlight with Jim Corbett 

Emulate CEO shares the organ-chip maker’s vision to understand and predict drug response.

From the Blog

Charting Our Path Forward: Determination and Resilience Attracts $82M Series E Funding 

CEO, Jim Corbett, shares how new funding will enable Emulate to expand research and development efforts to new heights.


Emulate Endorses Act Incentivizing Alternative Research Methods  

On March 10th, 2021 Rep. Alcee L. Hastings (D-Fla.) and Citizens for Alternatives to Animal Research (CAARE) hosted the “21st Century Alternatives to Animals in Biomedical Research” virtual briefing in support of the Humane Research and Testing Act, re-introduced by representatives Hastings and Vern Buchanan (R-Fla.).

FDA Modernization Act

Bill to Allow IND Application of Organ-Chip Data 

This new bill allows an applicant for market approval for a new drug to use methods other than animal testing to establish the drug’s safety and effectiveness. Under this bill, these alternative methods may include cell-based assays, organ chips and microphysiological systems, sophisticated computer modeling, and other human biology-based test methods.